{"transactions":[{"id":737891,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:17.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271160/ownership.xml","form_type":"4"}},{"id":737890,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:17.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":21210,"source":{"system":"sec-edgar","filing":"0001193125-26-271160","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271160/ownership.xml","form_type":"4"}},{"id":1109863,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:08.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086766","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086766/ownership.xml","form_type":"4"}},{"id":1482188,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:21:49.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072473/ownership.xml","form_type":"4"}},{"id":1845349,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T21:41:22.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":19203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":29205,"derivative":{"exercise_price":3.61,"expiration_date":"2033-06-20","underlying":"Common Shares","underlying_shares":19203},"source":{"system":"sec-edgar","filing":"0000899243-23-016419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016419/doc4.xml","form_type":"4"}},{"id":1845348,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-06-23T21:41:22.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":16544,"source":{"system":"sec-edgar","filing":"0000899243-23-016419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016419/doc4.xml","form_type":"4"}},{"id":2242589,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-06T20:11:12.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":34353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":62196,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034501/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2242588,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-06T20:11:12.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":774673,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."}],"balance_after":802516,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034501/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2242587,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-06T20:11:12.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":98198,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":126041,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034501/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2242586,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T20:11:12.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":133744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"8/12ths of the shares underlying the options vested and became exercisable on June 1, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/12th of the total shares vesting on each of June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":161587,"derivative":{"exercise_price":0.6,"expiration_date":"2027-05-31","underlying":"Subordinate Voting Shares","underlying_shares":133744},"source":{"system":"sec-edgar","filing":"0001209191-22-034501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034501/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2242585,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subordinate Voting Shares","published_at":"2022-06-06T20:11:12.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":43104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 8/12ths of the RSUs vested and became exercisable on June 1, 2022, with the remaining 4/12ths of the total RSUs vesting on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such vesting date."}],"balance_after":43104,"source":{"system":"sec-edgar","filing":"0001209191-22-034501","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034501/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2245060,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-04T01:26:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":34353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 2/3rds vested on June 1, 2022 and the remaining 1/3rd vests in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":62196,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034419/doc4.xml","form_type":"4"}},{"id":2245059,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-04T01:26:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":774673,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 36 months beginning on June 1, 2022. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan)."}],"balance_after":802516,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034419/doc4.xml","form_type":"4"}},{"id":2245058,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-06-04T01:26:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":98198,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. Of these DDSUs, 1/3rd vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":126041,"derivative":{"underlying":"Subordinate Voting Shares"},"source":{"system":"sec-edgar","filing":"0001209191-22-034419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034419/doc4.xml","form_type":"4"}},{"id":2245057,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-04T01:26:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":133744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"8/12ths of the shares underlying the options vested and became exercisable on June 1, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/12th of the total shares vesting on each of June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":161587,"derivative":{"exercise_price":0.6,"expiration_date":"2017-05-31","underlying":"Subordinate Voting Shares","underlying_shares":133744},"source":{"system":"sec-edgar","filing":"0001209191-22-034419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034419/doc4.xml","form_type":"4"}},{"id":2245056,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38198,"kind":"person","name":"Vallone Carol A","position":1,"cik":"0001422058","reported_name":"Vallone Carol A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subordinate Voting Shares","published_at":"2022-06-04T01:26:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":43104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 8/12ths of the RSUs vested and became exercisable on June 1, 2022, with the remaining 4/12ths of the total RSUs vesting on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such vesting date."}],"balance_after":43104,"source":{"system":"sec-edgar","filing":"0001209191-22-034419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919122034419/doc4.xml","form_type":"4"}}]}